VX17-659-105

  • What's involved: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation. (VX17-659-105)
  • Take part: Closed
  • Principal Investigator: Dr Helen Barr
Research Theme | Respiratory

What's involved

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation. (VX17-659-105)

Principal Investigator

Dr Helen Barr

Take part

Closed
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute